To Test Bioequivalence Between Two Tablet Formulations in the Treatment of Allergy

Inclusion Criteria: * Male or female subjects * Volunteers aged of at least 18 years but not older than 55 years * Subjects will have a Body Mass Index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2 * Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study * Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis) * Has signed and dated the informed consent document, indicating that the subject has been informed of all pertinent aspects of the study * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Exclusion Criteria: * Seated pulse rate below 45 bpm or higher than 90 bpm at screening * Seated blood pressure below 90/60 mmHg or higher than 140/90 mmHg at screening * Relationship to persons involved directly with the conduct of the study (i.e., principal investigator; sub-investigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson \& Johnson subsidiaries; and the families of each) * Presence of any tongue piercings * Presence of braces * Females who are pregnant or are lactating * Females of childbearing potential or males with a female partner of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study * Females who are pregnant according to a positive serum pregnancy test * Any medical history or condition, or use of any drug or medication, that the investigator determines could compromise subject safety or the evaluation of results.